Beta-blocker therapy preserves left ventricular ejection fraction in anthracycline-treated breast cancer patients
Beta-blockers May Protect Heart Function in Breast Cancer Patients
This meta-analysis of 772 patients found that beta-blocker therapy significantly preserved left ventricular ejection fraction (LVEF) in pati…
Beta-blockers may help protect heart muscle function in breast cancer patients who receive anthracyclines during their treatment.
Long-term exercise significantly attenuates cardiac troponin I elevation in anthracycline-treated breast cancer patients
Long-term Exercise May Protect Heart Health After Breast Cancer Treatment
This meta-analysis of randomized controlled trials evaluated the impact of long-term exercise on cardiac markers in breast cancer patients t…
Long-term exercise may help reduce certain markers of heart damage in breast cancer patients treated with anthracyclines.
Mitochondrial-targeted therapies may prevent doxorubicin cardiotoxicity via PANoptosis modulation
New strategies may protect heart health during chemotherapy treatment
This systematic review synthesizes evidence on mitochondrial-targeted strategies for doxorubicin-induced cardiotoxicity. It describes mechan…
Chemotherapy can damage the heart by disrupting mitochondria, but new research identifies several potential ways to shield the heart from th…
ACEIs and Beta Blockers Show Cardioprotective Effects in Chemotherapy
ACE Inhibitors and Beta Blockers May Protect Hearts During Chemotherapy
An umbrella review of 35 meta-analyses finds ACEIs and beta blockers modestly preserve cardiac function and reduce heart failure risk during…
Specific heart medications like ACE inhibitors and beta blockers may help protect heart function in patients undergoing chemotherapy treatme…
Retrospective analysis identifies risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients
Many Breast Cancer Patients Can Avoid Heart Damage — If Doctors Know the Warning Signs
This retrospective analysis of 298 HER2-positive breast cancer patients assessed trastuzumab-induced cardiotoxicity.
This could help doctors protect patients’ hearts before cancer therapy even begins.
Meta-analysis finds beta-blockers may reduce cardiotoxicity risk during cancer therapy
Heart-Protecting Meds Show Promise for Cancer Patients
A meta-analysis of 19 RCTs in patients receiving anthracyclines and/or trastuzumab found beta-blockers improved LVEF (WMD=2.19) and reduced…
Two specific heart medications stand out as the most effective shields against heart damage caused by powerful cancer treatments.
Questions about cardiotoxicity
Do beta-blockers improve heart function in patients with cardiotoxicity?
Beta-blockers may help preserve heart pumping function in some cancer patients receiving cardiotoxic chemotherapy, but the evidence is mixed and depends on the cause and setting of the heart damage.
Full answer →What are the risk factors for trastuzumab-induced cardiotoxicity?
The biggest risk factor for trastuzumab-induced cardiotoxicity is prior anthracycline chemotherapy; other risks include older age, existing heart disease, high blood pressure, diabetes, and smoking [9][10][11].
Full answer →